Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals
India's preferred Personal finance destination
Home Shares News Centre F&O Mutual Funds IPO Portfolio Commodity Loans Financial Planning Insurance About Us
Markets Companies Research Industries E-Mail Page
Wealth Tracker    Newsletter   Tax Corner NRI Centre Forums E-Mail Chat Masala Feedback
my Last 5 Scrips
Company BSE Price(Rs) % Chg
Hindalco 177.65 1.47
Tata Stl 536.80 1.59
Tata Pow 93.35 1.06
Ong Corp 424.45 0.15
Bharti A 370.75 0.88
Clear All Clear Last
Shares
NSE Live
Nifty Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
BSE Live
BSE30 Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
IPO Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Discussion Forum
Research
Research Reports
Sector Watch
Economy Watch
Snapshot-Lupin Limited
Lupin Limited
Sector:Pharmaceuticals Pharmaceuticals - Bulk Drugs
BSE:500257NSE:LUPINBloomberg:LPC@INReuters:LUPN.BO
Market Lot: 1Face Value: 2ISIN Demat: INE326A01037
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
18-AUG-14 Lupin said,'' That the company has granted 272210 options to the employees of its subsidiary company, under Lupin subsidiary companies employees stock option Plan 2011 at the exercise price of Rs 1164.80''. 06-AUG-14 Lupin, today announced a strategic distribution agreement with LG Life Sciences (South Korea) to launch Insulin Glargine, a novel insulin analogue under the brand name Basugine???. 30-JUL-14 During the quarter, the pro...   More..
Business Profile Future Plans
CEO Talk
Lupin Ltd is focusing on manufacturing products with high technology barriers through the non-infringing route.   D. B. Gupta
One To One
Recent news
Latest News
'Lupin's entry into insulin analogue market is a step in right direction'  -IRIS 07-Aug-14
Previous

More


Brief Financials (in Rs. Mn.)Detailed Quarterly
Period ending (months)31-Dec-2013(9)31-Mar-2013 (12)31-Mar-2012 (12)
Net sales 63557.2070104.9053158.90
Other Income4842.90233.1034.90
Total Income68400.1070338.0053193.80
Cost of goods sold44500.5052385.9042229.70
OPBDIT23899.6017952.1010964.10
PAT17530.5012604.308043.70
Gross Block---
Equity capital896.50895.10893.30
EPS (Rs.)-28.1918.02
DPS (Rs.)---
BV (Rs.)---
P/E range (x)-17.99 - 22.6622.45 - 29.56
Debt / Equity (x)---
Operating margin (% of OI)34.925.520.6
Net margin (% of OI)25.617.915.1
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
159, CST Road
Kalina
Santacruz (East)
Mumbai
Maharashtra-400 098
PHONE
(022) 6640 2323
FAX
(022) 2652 8806
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Trade On-line | Wealth Tracker | Newsletters | Tax Corner | NRI Centre | Forums | E-mail | Chat | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer